Hemab Therapeutics Holdings, Inc. Common Stock COAG · Stock Open Hemab Therapeutics Holdings, Inc. Common Stock in new tab
Hemab Therapeutics Holdings, Inc. Common Stock Analysis (COAG)
Is Hemab Therapeutics Holdings, Inc. Common Stock a good investment? Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is currently trading at 25.00 USD.
Earnings Schedule: Hemab Therapeutics Holdings, Inc. Common Stock is expected to release its next earnings report on Aug. 14, 2026.
Investor FAQ
Does Hemab Therapeutics Holdings, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hemab Therapeutics Holdings, Inc. Common Stock?
Hemab Therapeutics Holdings, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 14, 2026. The company currently has a trailing EPS of -2.33.
Company Profile
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Community Discussion